Unresectable Hepatocellular Carcinoma

• FDA approval · 2026-02-03
  FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  The FDA approved a supplemental application for STIVARGA (regorafenib) to expand its indications.

• FDA approval · 2020-07-21
  FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  FDA approved a supplemental application for Stivarga (regorafenib) from Bayer, expanding its approved uses.

• FDA approval · 2018-06-06
  FDA Approved: LENVIMA — Supplemental Application (Eisai Inc.)

  FDA approved a supplemental application for LENVIMA (lenvatinib) submitted by Eisai Inc.